Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery

Audrey Olshefsky, Christian Richardson, Suzie H. Pun, and Neil P. King*

ABSTRACT: Despite remarkable advances over the past several decades, many therapeutic nanomaterials fail to overcome major in vivo delivery barriers. Controlling immunogenicity, optimizing biodistribution, and engineering environmental responsiveness are key outstanding delivery problems for most nanotherapeutics. However, notable exceptions exist including some lipid and polymeric nanoparticles, some virus-based nanoparticles, and nanoparticle vaccines where immunogenicity is desired. Self-assembling protein nanoparticles offer a powerful blend of modularity and precise designability to the field, and have the potential to solve many of the major barriers to delivery. In this review, we provide a brief overview of key designable features of protein nanoparticles and their implications for therapeutic delivery applications. We anticipate that protein nanoparticles will rapidly grow in their prevalence and impact as clinically relevant delivery platforms.

INTRODUCTION

Over the past 30 years, tremendous advances in nanoparticle platforms for therapeutic applications have been achieved.\(^1,2\) In 1995, the first cancer-treating nanoparticle was approved by the FDA: Doxil, a liposomal formulation of doxorubicin that significantly decreased cardiomyopathy caused by free doxorubicin.\(^3,4\) Less than three decades later, the first two mRNA vaccines were approved by the FDA: Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax, advanced lipid nanoparticle formulations that deliver synthetic mRNA to elicit highly protective immune responses against SARS-CoV-2.\(^5,6\) Despite these and many other advances, it is widely believed that nanotherapeutics have yet to achieve their full potential due to the inconsistent translation from in vitro results in cell culture to in vivo results in animal models, and preclinical results in animal models to clinical efficacy in humans.\(^1,7,8\) The clinical translation of nanotherapeutics is fundamentally limited by several biological barriers to delivery, manifesting as a much lower than expected clinical trial success rate (Figure 1).\(^9\) Successful therapeutic delivery systems must (1) efficiently localize to the body compartment or organ of interest (e.g., tumor), (2) localize to the cell type of interest (e.g., cancer cells), and (3) engage with the target cells in a therapeutic manner (e.g., kill cancer cells). Overcoming these sequential biological barriers requires precise engineering to endow nanoparticles with functionalities suited to their therapeutic application. Self-assembling protein nanoparticles are an emerging class of delivery vehicles with the potential to satisfy these requirements through directed evolution and rational design.

Here, we define self-assembling protein nanoparticles as atomically precise, bounded assemblies composed of symmetric protein oligomers forming three-dimensional shells with hollow interiors. The term “protein nanoparticles” refers to these assemblies unless otherwise noted. As discussed further in “Protein nanoparticle architecture and geometry,” these assemblies have rotational symmetry axes projected into all three dimensions. Examples of such assemblies include computationally designed protein nanoparticles, and natural, nonviral protein nanocontainers like ferritin.\(^18−21\) Although albumin and silk fibroin nanoparticles are also composed of proteins, they do not form atomically precise nanoparticles with defined symmetries.\(^22,23\) Viral vector and virus-derived particle engineering are also outside the scope of this review due to their distinct complexity. However, we will draw comparisons between many viral and nonviral protein assemblies, as virus-derived delivery systems are a major source of inspiration. Therapeutic applications of these other protein-based nanotherapeutics are thoroughly reviewed elsewhere.\(^24−30\)

PART 1: DESIGNABLE FEATURES OF PROTEIN NANOPARTICLES

Introduction. Proteins are arguably the most information-rich molecules in the known universe. The information encoded in their amino acid sequences enables proteins to perform a
remarkable variety of sophisticated functions that largely constitute the molecular basis of life. The greater the ability to harness this information for precise design, the more sophisticated and diverse the encodable structures can be.\textsuperscript{31,32} Computational protein design has become a widely used technique that helps manage the complexity of protein structures and energetics and, in conjunction with complementary approaches, can be used to develop functionalities that can be integrated into protein nanoparticles.\textsuperscript{33}−\textsuperscript{36} The main features engineered for delivery purposes are physicochemical properties, environmental responsiveness, scaffold functionalization, and cargo encapsulation.\textsuperscript{37} In the following sections, we discuss how these features can be tuned and detail considerations for producing these materials at sufficient scale for clinical application.

**Protein Nanoparticle Scaffold Design.** To date, three primary approaches to designing and modifying protein nanoparticles have been explored in delivery applications: top-down modification of natural protein nanocontainers, bottom-up design of novel protein nanoparticles, and directed evolution of nanoparticle scaffolds to confer specific functions.

Currently, the most straightforward nanoparticle design method is top-down adaptation of an existing, naturally evolved viral capsid or cellular protein nanocontainer.\textsuperscript{38,39} Natural protein nanoparticles like ferritins, encapsulins, and lumazine synthases evolved over billions of years to serve highly specialized biological functions in specific environments, with many functionalities that would be virtually impossible to design using current methods.\textsuperscript{33,40−42} Natural protein nanoparticles can also be mutated or modified through the fusion of functional protein domains to confer additional properties. For example, Seo, Yoo, and Kim et al. reported a ferritin nanoparticle with a fused fibrinolytic domain to improve tumor accumulation of coadministered anticancer drugs.\textsuperscript{33} However, even modified natural protein nanocontainers are largely confined to a design space that is close to their initial states, making it challenging but not impossible to alter their fundamental structural and biochemical properties. Directed evolution, discussed below, has become a particularly powerful tool for modifying some of these underlying properties.

Recent advances in protein engineering have enabled the bottom-up design of purpose-built protein nanoparticles, drastically expanding the protein nanoparticle design space. These methods typically apply principles of symmetry to arrange natural or de novo designed cyclic oligomers into protein nanoparticles through interface design or rigid genetic fusion, reviewed in Khmelinskaia, Wargacki, and King (2021).\textsuperscript{43}−\textsuperscript{49} Padilla, Colovos, and Yeates et al. (2001) reported an early example of a self-assembling protein nanoparticle constructed using the rigid fusion of several oligomeric domains.\textsuperscript{48} Recently computational protein design has been applied to interface and rigid fusion methods enabling the design of increasingly complex protein nanoparticles with improving success rates.\textsuperscript{19,50,51} King and Baker et al. (2012) reported self-assembling protein nanoparticles with a variety of symmetries using computational protein interface design to arrange existing cyclic oligomers into the desired assemblies (Figure 2B).\textsuperscript{19} Many computational protein design methods currently require specific technical expertise and access to substantial computational resources. However, advances in machine learning are rapidly simplifying the protein design process and reducing the computational burden.\textsuperscript{52} This promises to make computational protein design a more widely accessible technique.
Directed evolution is a powerful tool for refining existing protein nanoparticles.\textsuperscript{53} This method has been used for a variety of modifications ranging from improving nanoparticle biodistribution, packaging, and protection of nucleic acid to the sequestration of toxic enzymes.\textsuperscript{54−56} Notably, Tetter, Terasaka, and Steinauer et al. recently reported the design and directed evolution of an icosahedral nanocontainer into a self-mRNA encapsidating nanoparticle with a diameter almost twice as large as the native structure.\textsuperscript{56,57} Directed evolution experiments require both a selection assay that will drive designs exclusively toward a desired function and an initial protein nanoparticle that is reasonably evolutionarily close to that function. Choosing a selection assay and initial protein nanoparticle is a nuanced process that requires careful consideration, and these experiments can be labor intensive. Alternatively, a well-designed directed evolution experiment is a powerful tool that can be used to select for poorly understood features that would currently be impossible with rational design alone.\textsuperscript{55,56} As demonstrated in many viral vector gene delivery studies, a good selection assay can refine thousands to millions of highly diverse protein variants in a single experiment, making this a powerful complement to computational protein nanoparticle design.\textsuperscript{58−61}

Protein Nanoparticle Architecture and Geometry. Nanoparticle geometry describes the arrangement of subunits composing a protein nanoparticle. All protein nanoparticles are constructed from many copies of an asymmetric unit that are arranged in a symmetric manner such that they form a closed, three-dimensional structure (Figure 2A–C). Tetrahedral, octahedral, icosahedral, and some dihedral symmetries are most often used to generate these closed structures.\textsuperscript{39,66,67} Cyclic homo-oligomers that can be incorporated into a protein nanoparticle usually need to be on a matched axis of symmetry. For example, a cyclic tetramer must be on the axis of 4-fold symmetry in an octahedrally symmetric nanoparticle and is not easily incorporated into tetrahedral and icosahedral nanoparticles. The symmetry group also determines the number of asymmetric units in a complete nanoparticle, and thus the valency of any ligands displayed on the surface of the nanoparticle. Though possible in other symmetry groups, icosahedral architectures are typically more easily designed to have large interior cavities and nonporous shells that can aid in cargo packaging and protection; the myriad naturally existing, icosahedral nanocontainers benefit from these advantages.\textsuperscript{42,63,64,68} While protein nanoparticle subunit size can vary widely, symmetry groups with larger numbers of asymmetric units will yield larger nanoparticles for a subunit of a given size.

The asymmetric unit is composed of one or more protein chains and at least two protein–protein interfaces oriented about axes of cyclic symmetry.\textsuperscript{69} An asymmetric unit may be

### Table 1. Selected Examples of Non-Viral Protein Nanoparticle Platforms\textsuperscript{a}

| Name                                      | Model\textsuperscript{62} | Global Symmetry | Number of Chains and Oligomers in Assembly | Diameter | PDB/EMDB | Ref. |
|-------------------------------------------|---------------------------|-----------------|--------------------------------------------|----------|----------|------|
| H. pylori ferritin                        | ![Image](image1.png)      | Octahedral      | 24 monomers arranged as 12 dimers          | 12 nm    | 1FHA     | 63   |
| T. maritima encapsulins                  | ![Image](image2.png)      | Icosahedral     | 60 monomers arranged as 12 pentamers       | 24 nm    | 3DKT     | 64   |
| A. aeolicus lumazine synthase (AaLS)     | ![Image](image3.png)      | Icosahedral     | 60 monomers arranged as 12 pentamers       | 15 nm    | 1HQK     | 65   |
| Evolved lumazine synthase NC-4           | ![Image](image4.png)      | Icosahedral     | 240 monomers arranged as 12 pseudopentamers and 20 trimers | 30 nm    | 7AAJ     | 98   |
| Computationally designed two-component nanoparticle | ![Image](image5.png) | Icosahedral | 120 monomers arranged as 20 trimers and 12 pentamers | 27 nm | 6P6F | 18.55 |
| Computationally designed antibody nanoparticle | ![Image](image6.png) | Icosahedral | 36 monomers arranged as 12 de novo trimers and 12 Fc dimers | 25 nm | In Ref. | 21   |

\textsuperscript{a}Nanoparticle models were made using UCSF ChimeraX.\textsuperscript{62}
made up of a single chain with two interfaces or have several chains with internal nonsymmetric protein–protein interfaces. 

As discussed further in “Manufacturing Protein Nanoparticles,” if an asymmetric unit is composed of two or more chains, the nanoparticle can in principle be assembled in vitro. The number of protein chains and their arrangement within the asymmetric unit determines how many unique fusion points (N and C termini) are available on the interior and exterior of the protein nanoparticle for the addition of functional domains.

**Interface Design and Modifications.** The high degree of cooperativity in protein nanoparticle assembly requires special consideration when designing protein nanoparticle interfaces. As with most protein–protein interface design, protein nanoparticle interface design has to date generally relied on hydrophobic packing of interface residues. However, protein nanoparticles assemble with a high degree of cooperativity, which results in efficient assembly of subunits with relatively weak interfaces but can result in kinetic trapping of partial or off-target assemblies if the intersubunit interface is too strong. Large hydrophobic interfaces between protein nanoparticle subunits can also interfere with soluble expression. Designing hydrophilic interfaces, as seen in many natural protein nanocontainers, could be one way to overcome this limitation.

Protein nanoparticle interface design can be leveraged to encode environmental responsiveness and nanoparticle functionalization. Protein nanoparticle interfaces can be either scavenged from existing protein–protein interfaces and rigidly fused to a nanoparticle subunit or computationally designed from scratch. This flexibility can enable protein nanoparticles to directly scaffold natural proteins such as antibodies, thus functionalizing the nanoparticle. Additionally, protein nanoparticle interfaces can be selected or designed to allow for controlled assembly and disassembly of the protein nanoparticle under specific environmental conditions. Ionic strength, pH, and metal-dependent protein nanoparticles have been investigated for applications in both packaging and selective drug delivery.

**Interior Modifications.** In addition to modifying protein subunit interfaces, useful features can be engineered into both the interior and exterior surfaces of nanoparticles through rational design or library selection. Interior modification approaches are largely inspired by viruses and virus-like particles. Three main strategies have been used to genetically modify protein nanoparticle interior and exterior
surfaces: point mutation, genetic fusion, and loop insertion. Due to the symmetry and repetitive nature of self-assembling protein nanoparticles, small modifications are often unlikely to destabilize protein subunits, but can cause significant functional changes. Genetic modifications often enable chemical conjugations and post-translational modifications, providing opportunities for functionalization that benefit from years of research and development in both academia and industry.

The interior nanoparticle surface is commonly modified to encapsulate specific materials (Figure 2E). It has been widely demonstrated that mutating interior-facing surface residues to hold a net charge facilitates electrostatic-mediated cargo encapsulation (e.g., encapsulation of supercharged fluorescent

| Table 2. Key Variables Influencing the Potential Outcomes and Applications of Self-Assembling Protein Nanoparticles |
|---------------------------------------------------------------|
| **Scaffold source**                                           | **Design strategy**                                               | **Modification of a natural scaffold** |
|                                                               |                                                                 |   - Simple and expedient source of protein nanoparticles     |
|                                                               |                                                                 |   - Have relatively fixed structural properties             |
|                                                               |                                                                 |   - Rational design                                         |
|                                                               |                                                                 |   - High degree of control over features of the nanoparticle|
|                                                               |                                                                 |   - Requires a fundamental understanding of the features    |
|                                                               |                                                                 |   - Can choose or design subunits that are more robust      |
|                                                               |                                                                 |   - Evolution                                               |
|                                                               |                                                                 |   - Allows selecting for incompletely understood behavior   |
|                                                               |                                                                 |   - Powerful complement to rational design                  |
|                                                               |                                                                 |   - Labor-intensive                                         |
|                                                               |                                                                 |   - Selection strategies can be nuanced                     |
|                                                               | **Source species**                                                | **Recombinant proteins with similarities to the patient's   |
|                                                               |                                                                 |   - proteins may elicit autoimmune responses               |
| **Scaffold architecture**                                     | **Nanoparticle symmetry group (geometry)**                        | **Types of cyclic oligomers that can be displayed**         |
|                                                               | **Subunits in asymmetric unit**                                   | **Valency of displayed ligands**                            |
|                                                               |                                                                 | **Interior cavity size and porosity**                       |
| **Interior and exterior modifications**                       | **Genetically encoded interior or exterior modifications**       | **Surface amino acid mutations**                            |
|                                                               |                                                                 | **Post-translational modifications**                        |
|                                                               |                                                                 | **Protein display (e.g., antigen, binding domain, enzyme)**|
|                                                               | **Chemical modifications**                                        | **Chemical conjugation: Maleimide conjugation to cysteines,**|
|                                                               |                                                                 | **NHS ester conjugation to lysines, etc.**                   |
|                                                               |                                                                 | **Surface display or cargo loading: Conjugation to polymers,**|
|                                                               |                                                                 | **PEG, small molecule drugs, etc.**                         |
|                                                               | **Choice of subunit(s) to modify**                                | **Modular modification, e.g., co-display of two different**|
|                                                               |                                                                 |   - protein domains (one on each subunit)                   |
| **Interface design and modification**                         | **Strength of interface**                                         | **Nanoparticle assembly efficiency and monodispersity**     |
|                                                               | **Hydrogen bond networks and metal chelation**                   | **Responsiveness to environmental factors (e.g., pH)**      |
| **Nanoparticle subunit choice**                               | **Physicochemical properties**                                   | **Hydrophobicity, charge, isoelectric point, and zeta**     |
|                                                               |                                                                 |   - potential affect colloidal stability in buffer solutions and biological fluids |
|                                                               |                                                                 | **Hydrophobicity and positive charge may increase unwanted cell and tissue accumulation** |
|                                                               | **Intrinsic subunit features**                                   | **Complex environmental sensing & interaction**             |
|                                                               |                                                                 | **Sophisticated functions (e.g., molecular recognition or catalysis)** |
| **Manufacturing**                                             | **Protein expression host organism**                             | **Expression of components in mammalian cells enables low endotoxin and native post-translational modifications** |
|                                                               | **Assembly strategy**                                             | **In vivo assembly upon expression inside E. coli allows for encapsulation of biomolecules like self-mRNA** |
|                                                               |                                                                 | **In vitro assembly enables high sample purity and precise control over subunit composition and encapsulated cargo** |
Table 3. Examples of Self-Assembling Protein Nanoparticles in the Clinic

| Scaffold                        | Example application                  | Clinical status                  |
|--------------------------------|--------------------------------------|----------------------------------|
| IS3 dru (compositionally designed nanoparticle) | Influenza vaccine 96                  | Phase 1 clinical trial (NCT04896086) |
| IS3-50 (compositionally designed nanoparticle) | SARS-CoV-2 vaccine 172               | Phase 3 clinical trial (NCT05007951) |
| eOD-GT8 60-mer (engineered envelope glycoprotein (Env)) | HIV vaccine 124                     | Phase 1 clinical trials (NCT05001373, NCT03547245) |
| Ferritin (modified natural protein nanoparticle) | Epstein-Barr virus (EBV) vaccine 121 | Phase 1 clinical trial (NCT04645147) |

Proteins or nucleic acids) (Figure 2E). Interior surface residues can also be mutated to include side chains capable of specific chemical reactions like copper-free click chemistry. Alternatively, larger domains like affinity peptides can be seamlessly integrated into the protein nanoparticle interior through genetic fusion. Genetic fusion of functional domains to the nanoparticle interior surface can either be bioactive themselves or enable specific cargo encapsulation such as mRNA and siRNA sequences.

**Exterior Modifications.** Interactions between nanoparticles and their surrounding environments are primarily mediated by the exterior surfaces of the nanoparticles (Figure 2F). Two common goals of exterior modifications are (1) to alter the physicochemical properties of the scaffold surface and (2) to display a molecular recognition domain (e.g., a pathogen-derived antigen or receptor targeting domain). Similar to interior modification strategies, surface point mutations, chemical conjugations, genetic fusions, and loop insertions are commonly used to modify exterior surfaces. These methods have been used to increase in vivo circulation half-life and to incorporate post-translational modifications like glycosylation, which has been reported to increase germinal center delivery for vaccine applications. Surface modifications also have important implications for immunogenicity. “Stealth” coatings like polyethylene glycol (PEG) are often conjugated to nanoparticle surfaces to increase circulation time and reduce immunogenicity, but this strategy is clinically limited since many humans are sensitized to PEG.

Displaying functional domains on nanoparticle surfaces controls specific biological interactions like targeted delivery to tumor vasculature or immune responses to pathogen-derived antigens in the context of nanoparticle vaccine delivery. As described above, the display of such domains is fundamentally linked to the symmetry and stoichiometry of the nanoparticle platform. Monomeric domains like tumor-targeting DARPin complexes are symmetry-agnostic, while the display of multimeric antigens like influenza hemagglutinin usually requires fusion to a symmetry-matched nanoparticle component and sometimes facilitates antigen stabilization. A recent counterexample demonstrated the symmetry-agnostic display of influenza antigens on the surface of a VLP through SpyCatcher-SpyTag conjugation, an alternative to the genetic fusion approach, which has proven to be another robust and versatile technology for modifying nanoparticle exteriors.

**Manufacturing Protein Nanoparticles.** Protein production efficiency impacts the cost and market distribution of a therapeutic, thereby determining its commercial viability. The main considerations in protein nanoparticle manufacturing are the dose, protein production, nanoparticle assembly, and purification. Vaccines typically require much smaller doses than other protein-based therapeutics such as monoclonal antibodies (micrograms vs hundreds of milligrams), making it easier to achieve commercially viable production efficiency. However, most of the clinical production of protein nanoparticle immunogens has occurred only in the past few years and there is still much to learn (e.g., National Clinical Trials (NCT) 05007951, 04896086, 03186781, 03814720, 04579250, 04784767, 04645147, 05001373, and 03547245 reported at clinical trials.gov).

Process development for manufacturing large-scale protein nanoparticle therapeutics must adhere to production efficiency requirements and current good manufacturing process (cGMP) standards. Fortunately, the ability to perform in vitro nanoparticle assembly offers several advantages for manufacturing multicomponent protein nanoparticles. In vitro assembly enables two (or more) standard recombinant biologics to be separately purified before nanoparticle assembly, benefiting from decades of research and development in manufacturing recombinant protein biologics like monoclonal antibodies. Assembling protein nanoparticles in vitro increases sample purity and gives engineers precise control over subunit composition and cargo encapsulation. While simple protein nanoparticle components can be successfully produced and purified in *E. coli*, many components require mammalian post-translational modifications and must be produced in eukaryotic cells. In vitro assembly also enables the generation of mosaic nanoparticles simply by mixing different component-antigen fusions together such that different antigens are codisplayed on the same nanoparticle scaffold. Phase I clinical trials are currently underway for mosaic influenza vaccines. Notably, SpyCatcher/SpyTag conjugation of antigens to nanoparticle scaffolds offers an alternative approach to in vitro mosaic assembly; mosaics generated using this method are anticipated to reach the clinic soon. While each therapeutic application will likely require unique process development, improving the manufacturing capabilities of protein nanoparticle immunogens will provide useful information to the entire field.

A distinguishing characteristic of protein nanoparticles is their complete genetic encodability. With the recent emergence of clinically validated techniques for delivering genetic information in vivo, this feature opens up a unique opportunity to deploy certain nanoparticle therapeutics and vaccines as nucleic acids. In concept, genetic delivery would streamline manufacturing and allow rapid prototyping and iteration in vivo. However, the inability to control or purify the translated
protein(s) in vivo emphasizes the importance of optimizing the sequence of the nanoparticle therapeutic during design, as this will determine critical functional features such as expression level, monodispersity, and stability.

**Part 1 Summary.** The key design variables for engineering self-assembling protein nanoparticles as therapeutics are summarized in Table 2. While computational design enables control over protein nanoparticle structure, purification and in vitro assembly methods enable control over the exact nanoparticle composition. As further discussed in "Therapeutic Applications of Protein Nanoparticles," the nanoparticle characteristics combined with the delivery method critically influence the pharmacokinetics, biodistribution, and efficacy of the protein nanoparticle therapeutic.

### Table 4. Platform Requirements for Therapeutic Applications of Protein Nanoparticles

| Application          | Translational status | Platform requirements                                                                 |
|----------------------|----------------------|----------------------------------------------------------------------------------------|
| Vaccine delivery     | Clinical trials      | • Stable display of antigens                                                            |
|                      |                      | • Drains to lymph nodes                                                                 |
|                      |                      | • Internalized by APCs                                                                  |
|                      |                      | • Compatible with adjuvant                                                              |
|                      |                      | • Does not elicit autoimmune responses against patients                                 |
| Receptor signaling   | Preclinical          | • Stable display of receptor agonist or antagonist                                       |
|                      |                      | • Localizes to target receptors                                                         |
| Small molecule       | Preclinical          | • Stable encapsulation of small molecules                                              |
| delivery             |                      | • Accumulates in target organ or cell type                                              |
|                      |                      | • Mechanism exists for small molecule release                                           |
|                      |                      |   ○ Carrier degradation                                                                 |
|                      |                      |   ○ Controlled release                                                                  |
| Biologics delivery   | Preclinical          | • Capacity to encapsulate biologic of interest                                          |
|                      |                      | • Accumulates in target organ or cell type                                              |
|                      |                      | • Endocytosis by target cells                                                           |
|                      |                      | • Endosomal escape                                                                      |
|                      |                      | • Controlled release of biologic                                                        |
| Theranostics         | Preclinical          | • Stably encapsulates contrast agent                                                    |
|                      |                      | • Accumulates in tissue(s) of interest                                                  |
|                      |                      | • Contrast agent signal is detectable in specific environment of interest               |
|                      |                      | • Performs desired function in specific environment (e.g., drug release)                |

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Qualitative impacts of nanoparticle size, shape, and surface charge on biodistribution. The general effects of surface physicochemical properties on biodistribution were comprehensively reviewed by Blanco, Shen, & Ferrari and qualitatively graphed as relative accumulation in major mouse organs.\(^\text{10}\) Data were included from gold nanoparticles, liposomes, polymer micelles, zwitterionic nanoparticles, hydrogel nanoparticles, and more. (A) Nanoparticles greater than about 150 nm in diameter show increased accumulation in the lungs, liver, and spleen, while nanoparticles less than 5 nm in diameter show rapid renal clearance. (B) Spherical nanoparticles tend to have the least uptake by major clearance organs compared to cylindrical and discoidal nanoparticles. (C) Nanoparticles with positively charged surfaces show much higher nonspecific uptake than nanoparticles with negatively charged or neutral surfaces. *Reprinted with permission.*\(^\text{10}\)

---

**Part 2: Therapeutic Applications of Protein Nanoparticles**

**Introduction.** In this section, we discuss five common applications of protein nanotherapeutics, the key design criteria that must be considered for each, and their development status. We summarize this information in Tables 3 and 4.

While many design criteria are unique to each application, several criteria are shared among all in vivo therapeutic applications. These criteria generally affect nanoparticle pharmacokinetics and biodistribution, which have been extensively studied using inorganic and polymeric nanoparticle platforms.\(^\text{10}–\text{17,16}\) The key physicochemical properties influencing these phenomena are shape, size, charge, hydrophobicity, rigidity, and specific molecular interactions. For reference, the physicochemical properties of protein nanoparticles are extremely diverse but are generally spherical, 10–30 nm in...
diameter, hold a net negative surface charge at physiological pH, have hydrophilic surfaces, and can be designed to include or exclude specific molecular interactions (e.g., display a binding domain to target a specific receptor). Regardless of delivery route, nanoparticles that are too hydrophobic, too positively charged, too large, or too small face significant delivery barriers such as aggregation, nonspecific cell uptake, liver and spleen accumulation, and kidney clearance (Figure 3). Nanoparticles ∼10–150 nm in diameter more efficiently travel from the delivery site to the target tissue (e.g., through blood, extracellular matrix, lymphatic system, or mucous membranes). Still, protein corona formation, immunogenicity, and clearance by the mononuclear phagocytic system (MPS) are critical barriers to most delivery systems.17,117,118 While certain overarching biodistribution phenomena like MPS clearance appear to be consistent between inorganic, polymeric, and protein nanoparticles, the surface chemistries of such nanoparticles are distinct. It is necessary to consider if, and how, findings in one class of materials (e.g., PLGA-based nanoparticles) translate to other classes of materials (e.g., self-assembling protein nanoparticles). Designing successful nanotherapeutic platforms is a balancing act between the design criteria, platform features, and fundamental delivery barriers.

**Vaccine Delivery.** The goal of vaccines is to safely teach the immune system how to protect against infection or disease upon subsequent encounter with a pathogen. While traditional vaccines derived from whole pathogens provide effective prevention against many diseases, these are inappropriate or have fallen short for several diseases due to factors including safety considerations, insufficient immune stimulation, poor antigen stability, or engineering and manufacturing limitations.119 Protein nanoparticle immunogens, which deliver antigen in a repetitive array by genetic fusion or chemical or protein–peptide conjugation to nanoparticle scaffolds, aim to address many of these limitations and have been shown to elicit protective immune responses (Figure 4).97,98,110,112–116 This approach taps into multiple features of the immune system that have evolved to detect "particulate" pathogens featuring repetitive antigenic determinants. First, upon intramuscular injection, protein nanoparticles are the ideal shape and size to be taken up by peripheral or lymph node dendritic cells (spherical, ∼20–150 nm in diameter).113 Additionally, multivalent antigen display facilitates detection of pathogen-associated molecular patterns; protein nanoparticle-mediated B cell receptor cross-linking has been demonstrated to cause stronger immune responses than those elicited by soluble antigens.117,118,128 Although live-attenuated and inactivated vaccines also benefit from these immunological phenomena, self-assembling protein nanoparticles are widely considered safer since there is no infectious agent. Protein nanoparticles also allow the use of antigens that are engineered in ways that may be incompatible with viral or bacterial growth, such as preusion-stabilized RSV F (Figure 4A).129,130 The engineered protein nanoparticle immunogen may possess, for example, increased stability, increasing immune exposure to the antigenic conformation or epitope against which an immune response is desired.99,131–133 Like VLP-based vaccines, the natural fit between the properties of self-assembling protein nanoparticles and vaccine delivery criteria is likely responsible for vaccines being the only application of protein nanoparticles that has advanced to the clinic to date—the delivery efficiency of vaccines is less fundamentally limited by immunogenicity compared to other therapeutic applications (Table 3).96,98,122,134–137 However, additional data on the development of antibody responses against nanoparticle scaffolds and their effects is needed.

Current vaccine delivery research with protein nanoparticle immunogens is focused on understanding the mechanisms that underlie their interactions with the immune system and developing new technological features that expand their capabilities.86,93,96,110,128,138–145 The modularity of self-assembling protein nanoparticles and increasingly precise methods for designing them are beginning to allow systematic testing of important features including nanoparticle architecture (e.g., icosahedral or tetrahedral scaffolds, which present antigen in distinct geometries), antigen identities and combinations (e.g., mosaic nanoparticle immunogens for broadly protective vaccines), post-translational modifications (e.g., glycosylation to increase germinal center accumulation), and surface modifications to tune immunogenicity or focus the immune response to specific sites of interest (e.g., molecular or steric shielding).138,93,96,110,124,146

**Small Molecule Delivery.** The hydrophobic nature of many small molecule drugs often results in poor solubility or nonspecific accumulation throughout the body, reducing therapeutic bioavailability, and increasing unwanted toxicities.147 Loading small molecules onto a carrier such as an

---

**Figure 4.** The DS-Cav1-I53−50 nanoparticle immunogen. (A) A vaccine against respiratory syncytial virus (RSV) was engineered by outwardly displaying a trimeric RSV antigen (DS-Cav1) on the trimeric subunit of a computationally designed nanoparticle (I53−50). (B) Negative stain electron microscopy of I53−50 and DS-Cav1-I53−50 nanoparticles. Left: representative micrographs. Right: averages of nanoparticle micrographs. (C–D) Antibody binding titers of DS-Cav-1-specific antibodies (C) or serum neutralizing antibodies (D) from mice immunized with bare nanoparticles (I53−50), free immunogen (DS-Cav1), or nanoparticle immunogens (DS-Cav1-I53−50) at valencies of 33%, 67%, or 100%. Each point represents and individual animal, geometric means are represented by horizontal lines and indicated at the bottom of the plots, and statistical significance is indicated: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See original publication for more details. Reprinted with permission.
antibody is an effective way to improve their biodistribution. However, the hydrophobic small molecule is often chemically conjugated to the surface of non-nanoparticle carriers, limiting drug loading capacity while also requiring careful optimization of drug-carrier ratio to maintain stability and desired biodistribution.

Protein nanoparticle carriers possess an interior cavity for encapsulation of hydrophobic small molecules (Figure 3E). For example, ferritin nanoparticles have been engineered to encapsulate doxorubicin, cisplatin, and other small molecule therapeutics. Drug-loaded ferritin nanoparticles have not yet been clinically approved due to complexity in manufacturing and specific tissue targeting, but promising advancements are underway.

Recently, a ferritin nanoparticle was engineered to display a fibrinolytic domain that can dissolve blood clots in tumors. The coadministration of liposomal doxorubicin (Doxil) with ferritin codisplaying clot-targeting and fibrinolytic domains (Figure 5). The synergy between these two delivery systems enabled small molecule delivery (by Doxil) and extracellular biologics delivery (by fibrinolytic activity), highlighting the potential of combination therapies.

**Extracellular Biologics Delivery.** Targeted stimulation or inhibition of cell signaling receptors is the key mechanism of many therapeutics ranging from receptor tyrosine kinase inhibitors to bispecific antibodies. Clinical translation of many such therapeutics is hindered by challenges with ligand stability, pharmacokinetics, biodistribution, and hepatotoxicity. Displaying receptor agonists or antagonists on protein nanoparticles offers several opportunities to address these challenges: the (ant)agonist can be stabilized by scaffolding on a solid foundation, the signaling magnitude can be tuned through altering display valency and nanoparticle architecture, and the biodistribution profile can be improved through optimizing the physicochemical features of the nanoparticle. Inspired by receptor signaling applications based on VLPs, ferritin and computationally designed nanoparticles have recently been engineered to display a variety of therapeutic receptor signaling domains. Examples include interleukin-4 receptor (IL-4R)-targeting peptides to ameliorate asthma symptoms, antimesenchymal epithelial transition (MET) peptide pharmacophores to stimulate hepatocyte growth factor receptor, death receptor ligands (TRAIL) to kill tumor cells, and angiopoietin-agonizing antibodies to promote angiogenesis.

**Intracellular Biologics Delivery.** The goal of intracellular biologics delivery is to package macromolecular drugs, target specific cell types, and deliver these membrane-impermeable molecules to specific subcellular locations for therapeutic effect. Viral vectors, virus-like particles, and lipid nanoparticles have been extensively developed for these applications, seeing clinical use as genetic vaccines, ex vivo gene editing for CAR-T cell therapies, and in vivo gene therapies. However, expansion of these technologies to new clinical applications is challenging due to MPS clearance and neutralizing antibody responses. Designed protein nanoparticles are a comparatively nascent technology but have the potential to dramatically expand the intracellular biologics delivery design space. Protein nanoparticles that deliver biologics such as siRNA to cultured cells through the endolysosomal pathway have been reported. Protein nanoparticles have also been reported with modifications that improve circulation half-life and target the nanoparticles to specific cells. For systemic in vivo delivery, protein nanoparticles need to incorporate design...

Figure 5. Coadministration of liposomal doxorubicin (Doxil) with ferritin codisplaying clot-targeting and fibrinolytic domains. (A) The ferritin monomer was engineered to display a clot-targeting peptide (CLT) and fibrinolytic domain (μP), resulting in surface display on ferritin nanoparticles. (B) Fibrinolytic nanocages (FNC) coadministered with Doxil show increased tumor cell accumulation and decreased fibrin signal compared to saline or Doxil controls. (C–D) When delivered to tumor-bearing mice at the indicated dosing schedule (C), Doxil-FNC coadministration showed increased tumor growth inhibition (purple) compared to mice treated with Doxil alone (red) and other controls (D). Reprinted with permission.
Figure 6. Computationally designed antibody cages (AbCs) activate apoptosis and angiogenic signaling pathways. (A and B) Caspase-3/7 is activated by AbCs formed with α-DR5 antibody (A), but not the free antibody, in RCC4 renal cancer cells (B). (C and D) α-DR5 AbCs (C), but not Fc AbC controls (D), reduce cell viability 4 days after treatment. (E) α-DR5 AbCs reduce viability 6 days after treatment. (F and G) α-DR5 AbCs enhance PARP cleavage, a marker of apoptotic signaling; (G) is a quantification of (F) relative to PBS control. (H) The F-domain from angiopoietin-1 was fused to Fc (A1F-Fc) and assembled into octahedral (o42.1) and icosahedral (i52.3) AbCs. (I) Representative Western blots show that A1F-Fc AbCs, but not controls, increase pAKT and pERK1/2 signals. (J) Quantification of (I): pAKT quantification is normalized to o42.1 A1F-Fc signaling (no pAKT signal in the PBS control); pERK1/2 is normalized to PBS. (K) A1F-Fc AbCs increase vascular stability after 72 h. (Left) Quantification of vascular stability compared with PBS. (Right) Representative images; scale bars, 100 μm. All error bars represent means ± SEM; means were compared using analysis of variance and Dunnett posthoc tests (tables S8 and S9). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. Reprinted with permission.21
features that provide stability during circulation with the ability to recognize, enter, and traffic within target cells. Viruses, VLPs, and some designed delivery vehicles achieve this by responding to the endosomal environment and switching states, satisfying the opposing needs of extracellular and endosomal activity. An exciting new space to explore with protein nanoparticles is engineering environmental responsive mechanisms, inspired by virus-derived particles.

**Theranostics.** Combining minimally invasive diagnostic techniques with therapeutic delivery, “theranostics” conveniently synergizes the strengths of two medical procedures. Noninvasive imaging techniques like magnetic resonance imaging (MRI) are vital for diagnosing and treating disease, yet have low resolution at the cellular and molecular level. Protein nanoparticles can provide alternative optical properties and could be engineered to inform researchers or physicians about real-time cellular and molecular processes through environmental responsiveness. However, knowledge on protein nanoparticle pharmacokinetics and biodistribution is often lacking. The ability to switch between “imaging mode” (e.g., encapsulating gadolinium) and “therapeutic mode” (e.g., encapsulating a small molecule drug), or to simultaneously operate in both modes, offers an opportunity to more deeply probe the in vivo behavior of protein nanoparticles. Ferritin was recently used in this manner to deliver a cytotoxic peptide to tumors while simultaneously displaying green fluorescent protein (GFP) (Figure 8A–C). The option to operate in imaging mode, therapeutic mode, or both also offers a potential strategy for screening patients for therapeutic response before treatment. Theranostics could be especially impactful in the field of solid tumor delivery, where the heterogeneity within and between tumor types remains a medical challenge. However, like most other delivery applications, clinical translation of protein nanoparticle theranostics is still fundamentally limited by scaffold immunogenicity.

**Remaining Challenges and Opportunities for Protein-Based Nanotherapeutics.** Adaptive and innate immune responses are perhaps the largest challenge for the broad application of protein nanoparticle therapeutics. Preclinical and clinical experience with therapeutics and vaccines based on viral vectors has clearly established vector-neutralizing antibodies as a significant limitation. Antibody responses against
the nanoparticle surface and MPS clearance would likely reduce therapeutic efficacy by preventing cargo delivery to the target tissues or cells. Altering physicochemical surface properties like lipid envelopes or glycosylation could significantly reduce such antibody responses. Although preliminary studies suggest that structural features such as aspect ratio and display of phagocytosis-preventing signaling molecules could reduce MPS clearance, new concepts and strategies will be needed to minimize the impact of immune responses against protein nanoparticle therapeutics. The growing body of data on protein nanoparticle vaccines—where immune responses are desirable instead of problematic—provides a valuable opportunity to learn how protein nanoparticles are perceived by the immune system. Lessons learned from these studies could be used to develop techniques for engineering immune evasion into protein nanoparticles.

Challenges in design and manufacturing hinder the development of efficacious protein nanotherapeutics. Although computational advances are broadening the accessibility of protein design, repurposing naturally existing protein nanocarriers and designing novel nanomaterials still require significant expertise and effort. Successfully designed protein nanotherapeutics must be manufactured from nucleic acid templates in biological systems, posing a challenge to meeting the demands of clinical production efficiency but offering opportunities for genetic delivery. Fortunately, molecular analysis and quality control of protein nanoparticles benefits greatly from the abundance of nanoscale analytical techniques. The monodisperse and atomically precise nature of protein nanoparticles enables straightforward and reliable use of analytical techniques, allowing for rapid design-build-test cycles.

There are many opportunities for meaningful advancement in the near future of protein nanoparticle engineering. Naturally occurring proteins and protein nanoparticles present innumerable examples of the sensitive and precise environmental responsiveness proteins can achieve; learning how to harness and engineer these kinds of responsiveness into protein nanoparticle therapeutics is a major opportunity for the field. Engineers are now able to selectively design and evolve nanoparticles with features such as larger interior cavities, nonspherical scaffolds, and specific responses to environmental cues of interest. Engineering and clinically translating self-assembling protein nanoparticles promises to be an exciting and abundant area of research over the next several years.

■ AUTHOR INFORMATION

Corresponding Author

Neil P. King – Institute for Protein Design and Department of Biochemistry, University of Washington, Seattle, Washington 98195, United States; Email: neil@ipd.uw.edu

Authors

Audrey Olshesky – Department of Bioengineering and Institute for Protein Design, University of Washington, Seattle, Washington 98195, United States; orcid.org/0000-0002-4028-5587

Christian Richardson – Department of Bioengineering and Institute for Protein Design, University of Washington, Seattle, Washington 98195, United States; orcid.org/0000-0003-0366-0330

Suzie H. Pun – Department of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, Washington 98195, United States; orcid.org/0000-0003-1443-4996

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.bioconjchem.2c00030

Notes

The authors declare the following competing financial interest(s): N.P.K. is a co-founder, shareholder, paid consultant, and chair of the scientific advisory board of Iconavax, Inc. The King lab has received an unrelated sponsored research agreement from Pfizer.

■ REFERENCES

(1) Mitchell, M. J.; Billingsley, M. M.; Haley, R. M.; Wechsler, M. E.; Peppas, N. A.; Langer, R. Engineering Precision Nanoparticles for Drug Delivery. Nat. Rev. Drug Discov. 2021, 20 (2), 101–124.
(2) Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer. Nat. Rev. Drug Discov. 2008, 7 (9), 771–782.
(3) Waterhouse, D. N.; Tardi, P. G.; Mayer, L. D.; Bally, M. B. A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form: Changing Toxicity Profiles. Drug Saf 2001, 24 (12), 903–920.
(4) Barenholz, Y. Doxi®—The First FDA-Approved Nano-Drug: Lessons Learned. J. Controlled Release 2012, 160 (2), 117–134.
(5) Office of the Commissioner. FDA approves first COVID-19 vaccine https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine (accessed 2021–01–02).
(6) Office of the Commissioner. Coronavirus (COVID-19) update: FDA takes key action by approving second COVID-19 vaccine https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-key-action-approving-second-covid-19-vaccine (accessed 03/01/2022).
(7) Paunovska, K.; Sago, C. D.; Monaco, C. M.; Hudson, W. H.; Castro, M. G.; Rudolts, T. G.; Kalathoor, S.; Vanover, D. A.; Santangelo, P. J.; Ahmed, R.; et al. A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation. Nano Lett. 2018, 18 (3), 2148–2157.
(8) Zhao, Z.; Uddeva, A.; Kim, J.; Mitragotri, S. Targeting Strategies for Tissue-Specific Drug Delivery. Cell 2020, 181 (1), 151–167.
(9) Bae, Y. H.; Park, K. Advanced Drug Delivery 2020 and beyond: Perspectives on the Future. Adv. Drug Deliv. Rev. 2020, 158, 4–16.
(10) Blanco, E.; Shen, H.; Ferrari, M. Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery. Nat. Biotechnol. 2015, 33 (9), 941–951.
(11) Reddy, S. T.; Swartz, M. A.; Hubbell, J. A. Targeting Dendritic Cells with Biomaterials: Developing the next Generation of Vaccines. Trends Immunol. 2006, 27 (12), 573–579.
(12) Qi, R.; Wang, Y.; Bruno, P. M.; Xiao, H.; Yu, Y.; Li, T.; Lauffer, S.; Wei, W.; Chen, Q.; Kang, X.; et al. Nanoparticle Conjugates of a Highly Potent Toxin Enhance Safety and Circumvent Platinum Resistance in Ovarian Cancer. Nat. Commun. 2017, 8 (1), 2166.
(13) Zhao, Y.; Wang, Y.; Ran, F.; Cui, Y.; Liu, C.; Zhao, Q.; Gao, Y.; Wang, D.; Wang, S. A Comparison between Sphere and Rod
Nanoparticles Regarding Their in Vivo Biological Behavior and Pharmacokinetics. Sci. Rep. 2017, 7 (1), 4131.

14. Gratton, S. E. A.; Ropp, P. A.; Pohlschau, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone, J. M. The Effect of Particle Design on Cellular Internalization Pathways. Proc. Natl. Acad. Sci. U. S. A 2008, 105 (33), 11613–11618.

15. Jiang, W.; Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W. Nanoparticle-Mediated Cellular Response Is Size-Dependent. Nat. Nanotechnol. 2008, 3 (3), 145–150.

16. Madathiparambil Visalakshan, R.; González García, L. E.; Benzarig, M. R.; Ghazaryan, A.; Simon, J.; Mierczynska-Vasilev, A.; Michl, T. D.; Vinu, A.; Mailänder, V.; Morsbach, S.; et al. The Influence of Nanoparticle Shape on Protein Corona Formation. Small 2020, 16 (25), 2000285.

17. Lazarovits, J.; Chen, Y. Y.; Sykes, E. A.; Chan, W. C. W. Nanoparticle-Blood Interactions: The Implications on Solid Tumour Targeting. Chem. Commun. 2015, 51 (14), 2756–2767.

18. Bae, J. B.; Gonen, S.; Liu, Y.; Sheffler, W.; Ellis, D.; Thomas, C.; Cacio, D.; Yeates, T. O.; Gonen, T.; King, N. P.; et al. Accurate Design of Megadalton-Size Two-Component Icosahedral Protein Complexes. Science 2016, 353 (6297), 389–394.

19. King, N. P.; Sheffler, W.; Sawaya, M. R.; Vollmar, B. S.; Sumida, J. P.; André, I.; Gonen, T.; Yeates, T. O.; Baker, D. Computational Design of Self-Assembling Protein Nanomaterials with Atomic Level Accuracy. Science 2012, 336 (6085), 1171–1174.

20. Sun, X.; Hong, Y.; Gong, Y.; Zheng, S.; Xie, D. Bioengineered Ferritin Nanocarriers for Cancer Therapy Int. J. Mol. Sci. 2021, 22 (13), 7023.

21. Divine, R.; Dang, H. V.; Ueda, G.; Fallas, J. A.; Vulovic, I.; Sheffler, W.; Saini, S.; Zhao, Y. T.; Raj, I. X.; Morawski, P. A. et al. Designed Proteins Assemble Antibodies into Modular Nanocages bioRxiv 2021. DOI: 10.1126/biorxIV.1009949.

22. Rowinsky, E. K.; Donehower, R. C. Paclitaxel (taxol). Annu. Rev. Med. 1995, 46, 37–57.

23. Lajoie, M. J.; Boyken, S. E.; Ovchinnikov, S.; Hao, J.; Bafna, K.; Norn, C.; Kang, A.; Bera, A. K.; Ellis, D.; Hutchinson, G. B.; Moyer, A.; Yasmeen, A.; Tsybovsky, Y.; et al. De Novo Design of Bioactive Protein Switches. Nature 2020, 572 (7768), 205–210.

24. Lajoie, M. J.; Boyken, S. E.; Salter, A. I.; Bruffey, J.; Rajan, A.; Langan, R. A.; Olshesky, A.; Muhunthan, V.; Bick, M. J.; Gewe, M.; et al. Designed Protein Logic to Target Cells with Precise Combinations of Surface Antigens. Science 2020, 369 (6511), 1637–1643.

25. Jumper, J.; Dongdević, S.; Conejos-Sánchez, I.; Vicent, M. J. Therapeutic Potential of Polypeptide-Based Conjugates: Rational Design and Analytical Tools That Can Boost Clinical Translation. Adv. Drug Delivery Rev. 2020, 160, 136–169.

26. Lajoie, M. J.; Boyken, S. E.; Benham, M. A.; Busch, F.; Jia, M.; Bick, M. J.; Choi, H.; Klima, J. C.; Chen, Z.; Walkey, C.; Mileant, A.; et al. De Novo Design of Tunable, pH-Driven Conformational Changes. Science 2019, 364 (6441), 658–664.

27. Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Zidek, A.; Hildebrand, R.; Falck, R.; M. A. G.; Hochberg, G. K. A.; et al. Designed Protein Logic to Target Cells with Precise Combinations of Surface Antigens. Science 2020, 369 (6511), 1637–1643.

28. Lee, E. J.; Guenther, C. M.; Suh, J. Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering. Curr. Opin. Biomed. Eng. 2018, 7, 58–63.

29. Douglas, T.; Young, M. Viruses: Making Friends with Old Foes. Nat. Rev. Microbiol. 2021, 19 (4), 237–247.

30. Wagner, H. J.; Weber, W.; Pusenberger, M. Synthetic Biology: Emerging Concepts to Design and Advance Adeno-Associated Viral Vectors for Gene Therapy. Adv. Sci. 2021, 8 (9), 2004018.

31. Huang, P.-S.; Boyken, S. E.; Baker, D. The Coming of Age of De Novo Protein Design. Nature 2016, 537 (7620), 320–327.

32. Jungper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Zidek, A.; Potapenko, A.; et al. Highly Accurate Protein Structure Prediction with AlphaFold. Nature 2021, 596 (7873), 583–589.

33. Seo, J.; Do Yoo, J.; Kim, M.; Shim, G.; Oh, Y.-K.; Park, R.-W.; Lee, B.; Kim, I.-S.; Kim, S. Fibrinolytic Nanocages Dissolve Clots in the Tumor Microenvironment, Improving the Distribution and Therapeutic Efficacy of Anticancer Drugs Exp. Mol. Med. 2021, 53105192.

34. Langan, R. A.; Boyken, S. E.; Ng, A. H.; Samson, J. A.; Dods, G.; Westbrook, A. M.; Nguyen, T. H.; Lajoie, M. J.; Chen, Z.; Berger, S.; et al. De Novo Design of Bioactive Protein Switches. Nature 2019, 572 (7768), 205–210.

35. Lee, E. J.; Guenther, C. M.; Suh, J. Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering. Curr. Opin. Biomed. Eng. 2018, 7, 58–63.

36. Van de Steen, A.; Khalife, R.; Colant, N.; Mustafa Khan, H.; Deveikis, M.; Charalambous, S.; Robinson, C. M.; Dabas, R.; Esteban Serna, S.; Catana, D. A.; et al. Bioengineering Bacterial Encapsulin Nanocompartments as Targeted Drug Delivery System. Synt. Syst. Biotechnol. 2021, 6 (3), 231–241.
et al. De Novo Protein Design by Deep Network Hallucination. *Nature 2021*, 600 (7889), 447–502.

(53) Packer, M. S.; Liu, D. R. Methods for the Directed Evolution of Proteins. *Nat. Rev. Genet. 2015*, 16 (7), 379–394.

(54) Wörsdörfer, B.; Woycickowsky, K. J.; Hilvert, D. Directed Evolution of a Protein Container. *Science 2011*, 331 (6017), 589–592.

(55) Butterfield, G. L.; Lajoie, M. J.; Gustafson, H. L.; Sellers, D. L.; Nattermann, U.; Ellis, D.; Bale, J. B.; Ke, S.; Lenz, G. H.; Yehdego, A.; et al. Evolution of a Designed Protein Assembly Encapsulating Its Own RNA Genome. *Nature 2017*, 552 (7685), 415–420.

(56) Tetter, S.; Terasaka, N.; Steinauer, A.; Bingham, R. J.; Clark, S.; Scott, A. J. P.; Patel, N.; Leibundgut, M.; Wroblewski, E.; Ban, N.; et al. Evolution of a Virus-like Architecture and Packaging Mechanism in a Repurposed Bacterial Protein. *Science 2021*, 372 (6547), 1220–1224.

(57) Terasaka, N.; Azuma, Y.; Hilvert, D. Laboratory Evolution of Virus-like Nucleocapsids from Nonviral Protein Cages. *Proc. Natl. Acad. Sci. U. S. A. 2018*, 115 (21), 5432–5437.

(58) Ojala, D. S.; Sun, S.; Santiago-Ortiz, J. L.; Shapiro, M. G.; Romero, P. A.; Schaffer, D. V. In Vivo Selection of a Computationally Designed SCHEMA AAV Library Yields a Novel Variant for Infection of Adult Neural Stem Cells in the SVZ. *Mol. Ther. 2018*, 26 (1), 304–319.

(59) Deverman, B. E.; Prado, P. L.; Simpson, B. P.; Kumar, S. R.; Chan, K. Y.; Banerjee, A.; Wu, W.-L.; Yang, B.; Huber, N.; Pasca, S. P.; Gradinaru, V. Cre-Dependent Selection Yields AAV Variants for Widespread Gene Transfer to the Adult Brain. *Nat. Biotechnol. 2016*, 34 (2), 204–209.

(60) Gustafson, H. L.; Olshesky, A.; Sylvestre, M.; Sellers, D. L.; Pun, S. H. Current State of In Vivo Panning Technologies: Designing Specificity and Affinity into the Future of Drug Targeting. *Adv. Drug Deliv. Rev. 2018*, 130, 39–49.

(61) Tabebordbar, M.; Lagerborg, K. A.; Stanton, A.; King, E. H.; Yeates, T. O. Geometric Principles for Designing Highly Tunable Protein Nanoparticle Formation. *ACS Nano 2018*, 12 (7), 6956–6967.

(62) Metz, S.; Rho, Y.; Jin, K. S.; Ahn, B.; Jung, S.; Kim, H.; Ree, M. pH-Dependent Structures of Ferritin and Apoferritin in Solution: Disassembly and Reassembly. *Biomacromolecules 2011*, 12 (5), 1629–1640.

(63) Sharma, J.; Uchida, M.; Miettinen, H. M.; Douglas, T. Modular Interior Loading and Exterior Decoration of a Virus-like Particle. *Nature Nanotech. 2017*, 12 (9), 1042–10430.

(64) McCoy, K.; Selivanovitch, E.; Luque, D.; Lee, B.; Edwards, E.; Caston, J. R.; Douglas, T. Cargo Retention inside P22 Virus-Like Particles. *Biomacromolecules 2018*, 19 (9), 3738–3746.

(65) Hermanson, G. T. Bioconjugate Techniques; Academic Press: Cambridge, MA, 2013.

(66) Drachman, J. G. Senter, P. D. Antibody-Drug Conjugates: The Chemistry behind Empowering Antibodies to Fight Cancer. *Hematology Am. Soc. Hematol. Educ. Program 2013*, 2013, 306–310.

(67) Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; Gad, A.; Chang, P. V.; Miller, I. A.; Lo, A.; Codelli, J. A.; Bertozzi, C. R. Copper-Free Click Chemistry for Dynamic in Vivo Imaging. *Proc. Natl. Acad. Sci. U. S. A. 2007*, 104 (43), 16793–16797.

(68) Zlotnick, A. Are Weak Protein-Protein Interactions the General Rule in Capsid Assembly? *Virology 2003*, 315 (2), 269–274.

(69) Deeds, E. J.; Bachman, J. A.; Fontana, W. Optimizing Ring Assembly Reveals the Strength of Weak Interactions. *Proc. Natl. Acad. Sci. U. S. A. 2012*, 109 (7), 2348–2353.

(70) Hagan, M. F.; Chandler, D. Dynamic Pathways for Viral Capsid Assembly. *Biophys. J. 2006*, 91 (1), 42–54.

(71) King, N. P.; Bale, J. B.; Sheffler, W.; McNamara, D. E.; Gonen, S.; Gonen, T.; Yeates, T. O.; Baker, D. Accurate Design of Co-Assembling Multi-Component Protein Nanomaterials. *Nature 2014*, 510 (7503), 103–108.

(72) Warzack, A. J.; Wörner, T. P.; van de Waterbeemd, M.; Ellis, D.; Heck, A. J. R.; King, N. P. Complete and Cooperative in Vitro Assembly of Computationally Designed Self-Assembling Protein Nanomaterials. *Nat. Commun. 2021*, 12 (1), 883.

(73) Zlotnick, A. Are Weak Protein-Protein Interactions the General Rule in Capsid Assembly? *Virology 2003*, 315 (2), 269–274.

(74) Deeds, E. J.; Bachman, J. A.; Fontana, W. Optimizing Ring Assembly Reveals the Strength of Weak Interactions. *Proc. Natl. Acad. Sci. U. S. A. 2012*, 109 (7), 2348–2353.
and Cargo Loading of Encapsulins Nanocompartments and Their Use for Rational Vaccine Design. Vaccine 2018, 36 (25), 3622–3628.

(126) Choi, B.; Moon, H.; Hong, S. J.; Shin, C.; Do, Y.; Ryu, S.; Kang, S. Effective Delivery of Antigen-Encapsulins Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection. ACS Nano 2016, 10 (8), 7339–7350.

(127) Bachmann, M. F.; Jennings, G. T. Vaccine Delivery: A Matter of Size, Geometry, Kinetics and Molecular Patterns. Nat. Rev. Immunol. 2010, 10 (11), 787–796.

(128) Kato, Y.; Abbott, R. K.; Freeman, B. L.; Haupt, S.; Groschel, B.; Silva, M.; Menis, S.; Irvine, D. J.; Schief, W. R.; Crotty, S. Multifaceted Effects of Antigen Valency on B Cell Response Composition and Size, Geometry, Kinetics and Molecular Patterns. Nat. Rev. Immunol. 2010, 10 (11), 787–796.

(130) Mukhamedova, M.; Wrapp, D.; Shen, C.-H.; Gilman, M. S.A.; Ambrozak, D. R.; Creanga, A.; et al. Mosaic Nanoparticle Display of Diverse Influenza Virus Hemagglutinins Elicits Broad B Cell Responses. Nat. Immunol. 2019, 20 (3), 362–372.

(133) Sesterhenn, F.; Yang, C.; Bonet, J.; Cramer, J. T.; Wen, X.; Kato, Y.; Abbott, R. K.; Lee, J. H.; Menis, S.; Skog, P.; Rossi, M.; Ota, T.; Bhullar, D.; Kalyuzhniy, O.; et al. Elicitation of Broadly Protective Sarbecovirus Immunity by Receptor-Binding Domain Nanoparticle Vaccines. Cell 2021, 184 (1), 5432–5447.

(134) Sliepen, K.; van Montfort, T.; Melchers, M.; Isik, G.; Sanders, R. W. Immunosilencing a Highly Immunogenic Protein Trimerization Domain. J. Biol. Chem. 2015, 290 (12), 7436–7442.

(135) Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and Its Formulations. Int. J. Pharm. 2019, 592, 1209–1215.

(138) Rogers, K.; O’Connor, M. A.; et al. Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial. Lancet 2019, 393 (10151), 229–240.

(139) Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; et al. Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial. Lancet 2019, 393 (10151), 229–240.

(142) Mu, Z.; Wiehe, K.; Saunders, K. O.; Henderson, R.; Cain, D. W.; Parks, R.; Martik, D.; Mansouri, K.; Edwards, R. J.; Newman, A. et al. Ability of Nucleoside-Modified mRNA to Encode HIV-1 Envelope Trimer Nanoparticles bioRxiv 20223810514.

(143) Wise, M. C.; Xu, Z.; Tello-Ruiz, E.; Beck, C.; Trautz, A.; Patel, A.; Elliott, S. T. C.; Choo, R. K.; Kim, S.; Kerkau, M. G. et al. In Vivo Delivery of Synthetic DNA-Encoded Antibodies Induces Broad HIV-1 Neutralizing Activity. J. Clin. Invest. 2019, 130 (2), 827–837.

(146) Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and Its Formulations. Int. J. Pharm. 2019, 592, 1209–1215.

(147) Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and Its Formulations. Int. J. Pharm. 2019, 592, 1209–1215.

(148) Horwitz, S.; O’Connor, O. A.; Pro, B.; Illidge, T.; Fanale, M.; Advari, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; et al. Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial. Lancet 2019, 393 (10151), 229–240.

(149) Hoggett, K.; van Montfort, T.; Melchers, M.; Isik, G.; Sanders, R. W. Immunosilencing a Highly Immunogenic Protein Trimerization Domain. J. Biol. Chem. 2015, 290 (12), 7436–7442.

(150) Kulp, D. W.; Bhullar, D.; Kalyuzhniy, O.; Havenar-Daughton, C.; et al. Elicitation of Broadly Protective Sarbecovirus Immunity by Receptor-Binding Domain Nanoparticle Vaccines. Cell 2021, 184 (1), 5432–5447.

(151) Liang, M.; Fan, K.; Zhou, M.; Duan, D.; Zheng, J.; Yang, D.; Feng, J.; Yan, X. H-Ferritin-Nanocaged Doxorubicin Nanoparticles Specifically Target and Kill Tumors with a Single-Dose Injection. Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (41), 14900–14905.

(152) Caldeira, J. C.; Perrine, M.; Pericle, F.; Cavallo, F. Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines Viruses 2020, 12 (5) DOI: 10.3390/v12050488.

(153) Schoonen, L.; van Hest, J. C. M. Functionalization of Protein-Based Nanocages for Drug Delivery Applications. Nanoscale 2014, 6 (13), 7124–7141.

(154) Ghosh, S.; Banerjee, M. A Smart Viral Vector for Targeted Delivery of Hydrophobic Drugs. Sci. Rep. 2021, 11 (1), 7030.

(155) Caldeira, J. C.; Perrine, M.; Pericle, F.; Cavallo, F. Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines Viruses 2020, 12 (5) DOI: 10.3390/v12050488.
Ligand-Specific Peptide Bunches for High Affinity and Biological Activity. *ACS Nano* 2013, 7 (9), 7462–7471.
(160) Rujas, E.; Kucharska, I.; Tan, Y. Z.; Benlekibir, S.; Cui, H.; Zhao, T.; Wasney, G. A.; Budylowski, P.; Guvenc, F.; Newton, J. C.; et al. Multivalency Transforms SARS-CoV-2 Antibodies into Ultrapotent Neutralizers. *Nat. Commun.* 2021, 12 (1), 3661.
(161) Zhao, Y. T.; Fallas, J. A.; Saini, S.; Ueda, G.; Somasundaram, L.; Zhou, Z.; Xavier Raj, I.; Xu, C.; Carter, L.; Wrenn, S.; et al. F-Domain Valency Determines Outcome of Signaling through the Angiopoietin Pathway. *EMBO Rep* 2021, 22 (12), e53471.
(162) Kaczmarczyk, S. J.; Sitaraman, K.; Young, H. A.; Hughes, S. H.; Chatterjee, D. K. Protein Delivery Using Engineered Virus-like Particles. *Proc. Natl. Acad. Sci. U. S. A* 2011, 108 (41), 16998–17003.
(163) Komatsu, Y.; Terasaka, N.; Sakai, K.; Mihara, E.; Wakabayashi, R.; Matsumoto, K.; Hilvert, D.; Takagi, J.; Suga, H. De Novo Peptide Grafting to a Self-Assembling Nanocapsule Yields a Hepatocyte Growth Factor Receptor Agonist. *iScience* 2021, 24 (11), 103302.
(164) Jensen, M. C.; Riddell, S. R. Designing Chimeric Antigen Receptors to Effectively and Safely Target Tumors. *Curr. Opin. Immunol.* 2015, 33, 9–15.
(165) Eyquem, J.; Mansilla-Soto, J.; Giavridis, T.; van der Stegen, S. J. C.; Hamieh, M.; Cunanan, K. M.; Odak, A.; Gönen, M.; Sadelain, M. Targeting a CAR to the TRAC Locus with CRISPR/Cas9 Enhances Tumour Rejection. *Nature* 2017, 543 (7643), 113–117.
(166) Edwardson, T. G. W.; Mori, T.; Hilvert, D. Rational Engineering of a Designed Protein Cage for siRNA Delivery. *J. Am. Chem. Soc.* 2018, 140 (33), 10439–10442.
(167) Levasseur, M. D.; Mantri, S.; Hayashi, T.; Reichenbach, M.; Hehn, S.; Waechterle-Men, Y.; Johansen, P.; Hilvert, D. Cell-Specific Delivery Using an Engineered Protein Nanocage. *ACS Chem. Biol.* 2021, 16 (5), 838–843.
(168) Cheng, Y.; Yumul, R. C.; Pun, S. H. Virus-Inspired Polymer for Efficient In Vitro and In Vivo Gene Delivery. *Angew. Chem., Int. Ed. Engl.* 2016, 55 (39), 12013–12017.
(169) Yuan, Y.-Y.; Mao, C.-Q.; Du, X.-J.; Du, J.-Z.; Wang, F.; Wang, J. Surface Charge Switchable Nanoparticles Based on Zwitterionic Polymer for Enhanced Drug Delivery to Tumor. *Adv. Mater.* 2012, 24 (40), 5476–5480.
(170) Banskota, S.; Raguram, A.; Suh, S.; Du, S. W.; Davis, J. R.; Choi, E. H.; Wang, X.; Nielsen, S. C.; Newby, G. A.; Randolph, P. B. et al. Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins. *Cell 2022 DOI: 10.1016/j.cell.2021.12.021.*
(171) Man, F.; Lammers, T.; de Rosales, R. T. M. Imaging Nanomedicine-Based Drug Delivery: A Review of Clinical Studies. *Mol. Imaging Biol.* 2018, 20 (5), 683–695.
(172) Diaz, D.; Vidal, X.; Sunna, A.; Care, A. Bioengineering a Light-Responsive Encapsulable Nanoreactor: A Potential Tool for In Vitro Photodynamic Therapy. *ACS Appl. Mater. Interfaces* 2021, 13 (7), 7977–7986.
(173) Putri, R. M.; Fredy, J. W.; Cornelissen, J. J. L. M.; Koay, M. S. T.; Katsonis, N. Labelling Bacterial Nanocages with Photo-Switchable Fluorophores. *ChemPhysChem* 2016, 17 (12), 1815–1818.
(174) Farhadi, A.; Ho, G.; Kunth, M.; Ling, B.; Lakshmanan, A.; Lu, G.; Bourdeau, R. W.; Schröder, L.; Shapiro, M. G. Recombinantly Expressed Gas Vesicles as Nanoscale Contrast Agents for Ultrasound and Hyperpolarized MRI. *AChE* J. 2018, 64 (8), 2927–2933.
(175) Bennett, K. M.; Shapiro, E. M.; Sotak, C. H.; Koretsky, A. P. Controlled Aggregation of Ferritin to Modulate MRI Relaxivity. *Biophys. J.* 2008, 95 (1), 342–351.
(176) Kaku, T. S.; Lim, S. Protein Nanoparticles in Molecular, Cellular, and Tissue Imaging. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol* 2021, 13 (5), e1714.
(177) Geninatti Crich, S.; Bussolati, B.; Tei, L.; Grange, C.; Esposito, G.; Lanzardo, S.; Camussi, G.; Aime, S. Magnetic Resonance Visualization of Tumor Angiogenesis by Targeting Neural Cell Adhesion Molecules with the Highly Sensitive Gadolinium-Loaded Apoferritin Probe. *Cancer Res.* 2006, 66 (18), 9196–9201.
(178) Elzoghby, A. O.; Hemasa, A. L.; Freag, M. S. Hybrid Protein-Inorganic Nanoparticles: From Tumor-Targeted Drug Delivery to Cancer Imaging. *J. Controlled Release* 2016, 243, 303–322.
(179) Hwang, M. P.; Lee, J.-W.; Lee, K. E.; Lee, K. H. Think Modular: A Simple Apoferritin-Based Platform for the Multifaceted Detection of Pancreatic Cancer. *ACS Nano* 2013, 7 (9), 8167–8174.
(180) Mingozzi, F.; High, K. A. Immune Responses to AAV Vectors: Overcoming Barriers to Successful Gene Therapy. *Blood* 2013, 122 (1), 23–36.
(181) Martino, A. T.; Markusic, D. M. Immune Response Mechanisms against AAV Vectors in Animal Models. *Mol. Ther. Methods Clin Dev* 2020, 17, 198–208.
(182) Rodrigues, P. L.; Harada, T.; Christian, D. A.; Pantano, D. A.; Tsai, R. K.; Discher, D. E. Minimal “Self” Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles. *Science 2013, 339 (6212), 971–975.*
(183) Nguyen, B.; Tolia, N. H. Protein-Based Antigen Presentation Platforms for Nanoparticle Vaccines. *NPJ Vaccines* 2021, 6 (1), 70.
(184) Laurens, M. B. RTS,S/AS01 Vaccine (Mosquirix TM): An Overview. *Hum. Vaccin. Immunother 2020, 16 (3), 480–489.*
(185) Inkscape Project, 2020. Inkscape, Available at: https://inkscape.org.